Medilink
Medilink A/S is a Danish family-owned pharmaceutical company founded in 1996 that develops, markets, and distributes four prescription medicines, including Aethoxysklerol® and Nitoman®, across ten EU countries via pharmacy and healthcare institution networks.
- Company typePrivate
- Founded1996
- HeadquartersBirkerød, Denmark
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Medilink does
Medilink A/S is a Danish family-owned pharmaceutical company founded in 1996 that develops, markets, and distributes prescription medicines. The company distributes four prescription medicines across ten European Union countries, with two named products in its portfolio: Aethoxysklerol® (polidocanol), a sclerosing agent administered by injection for the treatment of ruptured vessels and varicose veins in the legs, and Nitoman® (tetrabenazine), indicated for the treatment of involuntary muscle movements including vocal tics and abnormal body movements. The company is privately held by a family, with no parent company, institutional investors, or public listing disclosed.
The business operates a sales-led go-to-market model centered on direct engagement with healthcare professionals, including specialists, doctors, and pharmacists. Medilink maintains close dialogue with these stakeholders through educational meetings and professional exchange programs, and provides product information through government-approved regulatory websites in Denmark, Norway, Sweden, and Iceland. Pricing is not publicly disclosed by the company; customers are instead directed to national health authority pricing databases (e.g., medicinpriser.dk in Denmark), indicating a distribution model mediated through regulatory channels rather than direct commercial pricing. Distribution occurs via pharmacy and healthcare institution networks rather than direct-to-consumer channels.
Medilink maintains its registered office at Klintehøj Vænge 6, DK-3460 Birkerød, Denmark (company registration number 19 30 15 40), operates with 11-50 employees, and is GDPR compliant. The corporate technology footprint is minimal — a WordPress-based website, no mobile applications, no APIs or SDKs, no disclosed integrations, and no disclosed AI/ML capabilities. No funding rounds, M&A activity, partnerships, leadership changes, or restructuring events are recorded in the available data.
Medilink firmographics
Firmographics- Name
- Medilink
- Legal name
- Medilink A/S
- Website
- https://medilink.dk
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Medilink A/S is a Danish family-owned pharmaceutical company founded in 1996 that develops, markets, and distributes four prescription medicines, including Aethoxysklerol® and Nitoman®, across ten EU countries via pharmacy and healthcare institution networks.
- Ownership category
- akta.pro rank
Medilink industry classification
Industry- Product category
- Pharmaceutical Distribution
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Medilink is headquartered
LocationHeadquarters
- HQ city
- Birkerød
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
Medilink business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Prescription Medicine Distribution: Medilink A/S generates revenue through the development, marketing, and distribution of prescription medicines. The company distributes four prescription medicines across ten EU countries, with revenue derived from pharmaceutical distribution and sales.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Medilink product offering
Product offeringCore offering
Medilink A/S develops, markets, and distributes a portfolio of four prescription medicines across ten European Union countries. Its marketed products include Aethoxysklerol, a polidocanol-based sclerosing agent for varicose veins and ruptured vessels, and Nitoman, a tetrabenazine-based medication for involuntary muscle movements including vocal tics. The company engages healthcare professionals through educational meetings and professional exchange to communicate accurate product information.
Product overview
Medilink A/S is a Danish family-owned pharmaceutical company that develops, markets, and distributes prescription medicines. The company distributes four prescription medicines across ten EU countries. Its marketed product portfolio includes Aethoxysklerol® (polidocanol for treatment of varicose veins and ruptured vessels) and Nitoman® (tetrabenazine for treatment of involuntary muscle movements). Medilink emphasizes close dialogue with healthcare professionals through educational meetings and professional exchange to ensure accurate information reaches providers, patients, and their relatives.
Differentiator
Problem solved
Functional benefit
Products and services
- Aethoxysklerol A sclerosing agent containing polidocanol administered via injection for the treatment of ruptured vessels and varicose veins in the legs. It is a prescription medicine distributed by Medilink A/S across ten EU countries to healthcare professionals via pharmacy channels.
- Nitoman A prescription medication containing tetrabenazine used for treatment of involuntary muscle movements, including abnormal or slow movements of the body, arms, and legs, as well as unintentional sounds and speech associated with vocal tics. Distributed by Medilink A/S to healthcare professionals across ten EU countries.
Companies that use Medilink
Customer profileSegments2 records
Ideal customer profiles1 record
Medilink technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Medilink partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights3 records
Medilink competitors and assessment
Company assessmentRegional players
- Orifarm Group: Orifarm is a Danish pharmaceutical company with parallel-import, generics, and specialty distribution operations across Europe. Comparable to Medilink as a Denmark-headquartered pharma distributor operating across multiple EU markets with a focus on prescription medicines.
Broad incumbents
- STADA Arzneimittel: STADA is a major European generics and specialty pharma company distributing prescription medicines across the EU. Comparable to Medilink as an EU-wide prescription medicine distributor with portfolio breadth across therapeutic areas.
- Ferring Pharmaceuticals:
Direct peers
- Swedish Orphan Biovitrum (Sobi): Sobi is a Swedish specialty biopharmaceutical company focused on rare diseases and niche therapeutic areas. Comparable to Medilink as a Nordic-headquartered company commercializing specialty prescription medicines across European markets, though at a much larger scale.
- Nordic Drugs (Cross Pharma): Nordic Drugs is a Nordic specialty pharmaceutical company that markets and distributes prescription medicines in niche therapeutic areas. Directly comparable to Medilink as a small, privately held Nordic pharma distributor focused on underserved indications.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Medilink social profiles
Digital presenceMedilink compliance and trust
Trust signalCompliance1 record
Medilink financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medilink leadership team
Management profileNumber of profiles
Medilink funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medilink M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medilink
What does Medilink do?
Medilink A/S develops, markets, and distributes a portfolio of four prescription medicines across ten European Union countries. Its marketed products include Aethoxysklerol, a polidocanol-based sclerosing agent for varicose veins and ruptured vessels, and Nitoman, a tetrabenazine-based medication for involuntary muscle movements including vocal tics. The company engages healthcare professionals through educational meetings and professional exchange to communicate accurate product information.
Is Medilink a public or private company?
Medilink is a private company. It is classified as family owned and is currently operating.
When was Medilink founded?
Medilink was founded in 1996. It employs 11 to 50 people.
Where is Medilink based?
Medilink is headquartered in Birkerød, Denmark, in the Europe region.
How does Medilink make money?
One revenue line is on record: prescription Medicine Distribution.
Who are Medilink's main competitors?
Orifarm Group is listed as a regional player. Broad incumbents are STADA Arzneimittel and Ferring Pharmaceuticals. Direct peers are Swedish Orphan Biovitrum (Sobi) and Nordic Drugs (Cross Pharma).
Does Medilink have an API?
No public API is recorded for Medilink.
What industry is Medilink in?
Medilink's product category is Pharmaceutical Distribution. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.